SCHEMBL13305685

SCHEMBL13305685

Cc1cnn2c(NCc3cnc(N)nc3)cc(C3CCCN(C(=O)OCc4ccccc4)C3)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP3K12 Q12852 4/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ CDK2 P24941 2/20 0.41
▸ CHEK1 O14757 1/20 0.41
▸ CCNA2 P20248 1/20 0.41
▸ CCNA1 P78396 1/20 0.41
▸ JAK2 O60674 2/20 0.41
▸ JAK1 P23458 2/20 0.41
▸ TYK2 P29597 2/20 0.41
▸ JAK3 P52333 2/20 0.41
▸ GSK3B P49841 3/20 0.41
▸ LCK P06239 1/20 0.39
▸ USP30 Q70CQ3 1/20 0.39
▸ CDK9 P50750 2/20 0.39
▸ CCNT1 O60563 1/20 0.39
▸ TRPC3 Q13507 2/20 0.39
▸ TRPC7 Q9HCX4 2/20 0.39
▸ BCL9 O00512 1/20 0.38
▸ CTNNB1 P35222 1/20 0.38
▸ PDE4B Q07343 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12953762 0.91 GSK3B (0.51) MAP3K12MAPK1CDK2CHEK1CCNA2
SCHEMBL13304793 0.91 MAPK1 (0.41) MAP3K12MAPK1CDK2CHEK1CCNA2
SCHEMBL13305223 0.85 TRPC3 (0.44) MAP3K12MAPK1CDK2CHEK1CCNA2
SCHEMBL12953558 0.84 GSK3B (0.50) MAPK1CDK2CHEK1CCNA2CCNA1
SCHEMBL12953266 0.80 GSK3B (0.51) CDK2CHEK1CCNA2CCNA1JAK2
SCHEMBL12954179 0.80 GSK3B (0.67) CDK2GSK3B
SCHEMBL14607246 0.78 GSK3B (0.53) MAP3K12CDK2CHEK1CCNA2CCNA1
SCHEMBL14412769 0.77 GSK3B (0.47) MAPK1CDK2CHEK1CCNA2CCNA1
SCHEMBL14418651 0.76 GSK3B (0.55) CDK2CHEK1CCNA2CCNA1GSK3B
SCHEMBL12953255 0.76 CHEK1 (0.48) CDK2CHEK1CCNA2CCNA1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537116-B1 PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES SCHERING CORP (US) 2010-06-02 — — EP disclosed
Send feedback